METHOD FOR EARLY DIAGNOSTICS OF NEONATAL SEPSIS Russian patent published in 2021 - IPC G01N33/68 G01N33/92 G01N33/573 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to neonatology, and can be used for early diagnosis of neonatal sepsis. Biological material is taken from a newborn. Then, using the enzyme-linked immunosorbent assay technology, the level of the following inflammatory markers is determined in the biological material: Presepsin (S-CD14), Interleukin-18 (IL-18) and Serum amyloid-A (SAA). At a concentration of Interleukin-18 over 60 pg/ml, and Presepsin and Serum amyloid-A (SAA) over 600 pg/ml, the onset of a septic process is diagnosed. To determine S-CD14, IL-18 and SAA, blood can be used as a biological material, and urine can be used to determine IL-18 and SAA. Determination of markers can be carried out immediately after birth and then 24 and 72 hours after birth. To assess the effectiveness of treatment, the determination of markers of inflammation can be carried out in the course of the ongoing antibiotic therapy.

EFFECT: method provides the possibility of increasing the accuracy and sensitivity of diagnosis, reducing the time of the study, as well as reducing the number of false positive results obtained by determining S-CD14, IL-18 and SAA in the blood or urine of a newborn by enzyme immunoassay.

5 cl, 1 ex